Neuroendocrine Tumors – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Neuroendocrine Tumors – Drugs In Development, 2023’, provides an overview of the Neuroendocrine Tumors pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects
- The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAadi Bioscience Inc
AbbVie Inc
Adagene Suzhou Ltd
ADC Therapeutics SA
Advanced Accelerator Applications SA
Agastiya Biotech LLC
Alphamab Oncology
Amolyt Pharma
Aquestive Therapeutics Inc
Ariceum Therapeutics GmbH
ASCIL Biopharm
AstraZeneca Plc
AVEO Pharmaceuticals Inc
BeiGene Ltd
Beijing Foreland Pharma Co Ltd
Biotheus Inc
Boehringer Ingelheim International GmbH
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Camurus AB
CASI Pharmaceuticals Inc
Cbiomex Co Ltd
Chiesi Farmaceutici SpA
Chimeric Therapeutics Ltd
Chimerix Inc
Crinetics Pharmaceuticals Inc
Curasight
Eisai Co Ltd
Eli Lilly and Co
Elicera Therapeutics AB
Enterome Bioscience SA
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Fukushima Medical University
Full-Life Technologies Ltd
GSK plc
Harbour BioMed (Guangzhou) Co Ltd
HEC Pharma Co Ltd
Heilongjiang ZBD Pharmaceutical Co Ltd
Hutchison MediPharma Ltd
Imagine Pharma LLC
Immunwork Inc
Innovent Biologics Inc
Inspirna Inc
INVENT Pharmaceuticals Inc
Ipsen SA
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori Srl
Jiangsu Hengrui Medicine Co Ltd
Jubilant DraxImage Inc
Jubilant Therapeutics Inc
KAI Biotech Co Ltd
KisoJi Biotechnology Inc
Kite Pharma Inc
Leads Biolabs Inc
Loxo Oncology Inc
Max Delbruck Center for Molecular Medicine
Merck & Co Inc
Merck KGaA
MimiVax LLC
Mina Therapeutics Ltd
Molecular Targeting Technologies Inc
NanoValent Pharmaceuticals Inc
Novartis AG
Ology Bioservices Inc
Orano Med LLC
Oryzon Genomics SA
Perspective Therapeutics Inc
Pfizer Inc
Pharma Mar SA
POINT Biopharma Global Inc
Propanc Biopharma Inc
Provectus Biopharmaceuticals Inc
Qilu Pharmaceutical Co Ltd
Rani Therapeutics LLC
Regulaxis SAS
SciClone Pharmaceuticals Holdings Ltd
Seneca Therapeutics Inc
Shandong Buchang Pharmaceutical Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Jiao Tong University School of Medicine
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Tyercan Biopharm Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Sichuan Kelun Pharmaceutical Co Ltd
Stemline Therapeutics Inc
Suntec Medical (Taiwan) Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Taiho Oncology Inc
Takeda Pharmaceutical Co Ltd
Teclison Ltd
TerSera Therapeutics LLC
University of Pittsburgh
Vanquish Oncology Inc
Vyriad Inc
Wuxi Biocity Biopharma Co Ltd
Xencor Inc
Y-Biologics Inc